Definitely more fun to party with.
GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
Man you can't make this stuff up.
I apparently added an extra 0 to my email to my brother-in-law concerning IOVA.
Worst RSI of any sector = Biotech
and GBA is LONG 3000 shares IOVC!!!!!~!!!!!
I apparently added an extra 0 to my email to my brother-in-law concerning IOVA.
Worst RSI of any sector = Biotech
and GBA is LONG 3000 shares IOVC!!!!!~!!!!!
HOLY SHIT. THIS IS THE ULTIMATE TEST OF THE SAVANT METRICS...
... janes will you join me in IOVA? If this blows upwards I would feel better knowing others are involved and if it just blows up ,I again would feel better with others in...
A quick summery---
Solid Tumors are the holy grail in Cancer Bio's--> The company's TIL platform has demonstrated broad utility in multiple solid tumors
Co is in talks with the FDA concerning potency assay -some agreement must be made about dosage levels. Discussions are a key regulatory event.
Jan 10-- Iovance appoints Raj Puri as EVP, regulatory strategy, translational medicine 01/10 IOVA Iovance Biotherapeutics announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translational Medicine. Dr. Puri will begin his employment with the Company toward the end of the first quarter of 2022. For more than 19 years, Dr. Puri has served as the director of the Division of Cellular and Gene Therapies in the Office of Tissues and Advanced Therapies at the United States Food and Drug Administration in its Center for Biologics Evaluation and Research. He is also a Chief of Tumor Vaccines and Biotechnology Branch within DCGT.
That's right they hired someone who worked at the FDA for 19 years.... Do I have your attention now? I've been in this game along time....
Last anlyst action 1/28--> Iovance Biotherapeutics upgraded to Buy from Hold at Stifel 01/28 IOVA Stifel analyst Benjamin Burnett upgraded Iovance Biotherapeutics to Buy from Hold with a price target of $25, up from $23. The analyst views the hire of Dr. Raj Puri as a "vote of confidence from someone knowledgeable of the potency assay situation." He now thinks the worst-case scenario is less likely. The two most likely scenarios that could play out from here are: Iovance announces alignment with FDA and files the Biologics License Application as expected, or the company announces there's more potency validation work needed and they push the application, Burnett tells investors in a research note. He's now more optimistic that the application is a matter of when, not if.
A quick summery---
Solid Tumors are the holy grail in Cancer Bio's--> The company's TIL platform has demonstrated broad utility in multiple solid tumors
Co is in talks with the FDA concerning potency assay -some agreement must be made about dosage levels. Discussions are a key regulatory event.
Jan 10-- Iovance appoints Raj Puri as EVP, regulatory strategy, translational medicine 01/10 IOVA Iovance Biotherapeutics announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translational Medicine. Dr. Puri will begin his employment with the Company toward the end of the first quarter of 2022. For more than 19 years, Dr. Puri has served as the director of the Division of Cellular and Gene Therapies in the Office of Tissues and Advanced Therapies at the United States Food and Drug Administration in its Center for Biologics Evaluation and Research. He is also a Chief of Tumor Vaccines and Biotechnology Branch within DCGT.
That's right they hired someone who worked at the FDA for 19 years.... Do I have your attention now? I've been in this game along time....
Last anlyst action 1/28--> Iovance Biotherapeutics upgraded to Buy from Hold at Stifel 01/28 IOVA Stifel analyst Benjamin Burnett upgraded Iovance Biotherapeutics to Buy from Hold with a price target of $25, up from $23. The analyst views the hire of Dr. Raj Puri as a "vote of confidence from someone knowledgeable of the potency assay situation." He now thinks the worst-case scenario is less likely. The two most likely scenarios that could play out from here are: Iovance announces alignment with FDA and files the Biologics License Application as expected, or the company announces there's more potency validation work needed and they push the application, Burnett tells investors in a research note. He's now more optimistic that the application is a matter of when, not if.
IDEA #2----> Mrs Stoney says stop dickering around and put SWEET GREEN in that GREEN GARDEN! No day trade!
Enjoy the Salad Days of a Fresh IPO with Sweetgreen
This was my first big buy it was $28 but then it sold off and I bought more.....
Quotes from the Granny's Shorts mailbag.
Dear Zandy,
When you do your FA I listen. Thank goodness I have you. Cramer said buy it at $48.
Stoney got in at $27 though?
What was he basing it on? Didn't he listen to you?
Should I buy now at $8.80?
Hot for Zandy,
-Zoey in Zanzibar City
GRWG=====> $8.82
Dear Zandy,
When you do your FA I listen. Thank goodness I have you. Cramer said buy it at $48.
Stoney got in at $27 though?
What was he basing it on? Didn't he listen to you?
Should I buy now at $8.80?
Hot for Zandy,
-Zoey in Zanzibar City
GRWG=====> $8.82
WHO IS WITH ME!!!
Iovance Biotherapeutics, Inc. (IOVA)
17.18+0.88(+5.40%)<--------
As of 11:53AM EST.
UBER TONIGHT!!!! GET IN!
Iovance Biotherapeutics, Inc. (IOVA)
17.18+0.88(+5.40%)<--------
As of 11:53AM EST.
UBER TONIGHT!!!! GET IN!
it's almost time for DIS to report... place your bets. my take is, it tanks. DIS historically was bouncing around the $100 range and got a big bump in price attributable in some respect to joining the streaming wars and finding a tech-like PE that is today 133 (according to marketwatch). NFLX is the obvious streaming play, and we saw how that went. SE also got dumped to some degree on disappointing streaming. ROKU is down 70%. pay the piper DIS -- time to go back to the PE's of yore. in case you're wondering, reddit seems to like the calls.